01 November 2005
Inherited antithrombin deficiency and end stage renal disease.
Tomohiko Hara, Katsusuke NaitoMed Sci Monit 2005; 11(11): RA346-354 :: ID: 430402
Abstract
Antithrombin is a potent inhibitor of the coagulant effect of thrombin.In the latter half of 20(th) century, many families have been described in which an autosomaly dominantinherited antithrombin deficiency has caused severe venous thromboembolic disease in successive generations.The important complication is severe venoocclusive disease by deep venous thrombus. Some inherited antithrombindeficient patients developed renal failure because of fibrin deposition in the kidney glomeruli or renalvein thrombus, and therefore the need for replacement therapy for end stage renal disease (ESRD). Althoughan inherited antithrombin deficiency with renal failure is rare, prevention against renal failure insuch patients, and their renal replacement therapy for ESRD are important. Proteinuria decreases plasmaantithrombin level leading to more severe hyper-coagulation state. Therefore early in renal disease,it may be prudent for adaptation of anti-coagulation therapy even if recurrent thrombosis has not occurred.All replacement therapy (hemodialysis, transplantation or peritoneal dialysis) for ESRD are availablefor such thrombophilic disorders. Anticoagulation agents working without aggravation of antithrombineffects (Argatroban, Nafamostat mesilate etc.) are useful for hemodialysis. The renal allograft recipientswith thrombophilia seem to be at risk of developing an acute rejection or other vascular event. Peritonealdialysis is potentially a good adaptation for such thrombophilic disorders. However which therapy hasthe best mortality and morbidity outcomes is not clear. Physicians and Surgeons must pay attention tothe coagulation state and thrombophilia in ESRD patients, give strong consideration for adequate anti-coagulationtherapy and review the best renal replacement modality for each patient.
Keywords: Antithrombins - metabolism, Antithrombin III Deficiency - genetics, Kidney Failure, Chronic - therapy, Kidney Transplantation, Renal Dialysis, Venous Thrombosis - therapy
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952